JPWO2019182981A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2019182981A5
JPWO2019182981A5 JP2020550082A JP2020550082A JPWO2019182981A5 JP WO2019182981 A5 JPWO2019182981 A5 JP WO2019182981A5 JP 2020550082 A JP2020550082 A JP 2020550082A JP 2020550082 A JP2020550082 A JP 2020550082A JP WO2019182981 A5 JPWO2019182981 A5 JP WO2019182981A5
Authority
JP
Japan
Prior art keywords
melanoma
pharmaceutical composition
composition according
dapansutrile
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020550082A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021518374A5 (https=
JP7229565B2 (ja
JP2021518374A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/022770 external-priority patent/WO2019182981A1/en
Publication of JP2021518374A publication Critical patent/JP2021518374A/ja
Publication of JP2021518374A5 publication Critical patent/JP2021518374A5/ja
Publication of JPWO2019182981A5 publication Critical patent/JPWO2019182981A5/ja
Application granted granted Critical
Publication of JP7229565B2 publication Critical patent/JP7229565B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020550082A 2018-03-21 2019-03-18 メラノーマを治療するための方法 Active JP7229565B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862645999P 2018-03-21 2018-03-21
US62/645,999 2018-03-21
PCT/US2019/022770 WO2019182981A1 (en) 2018-03-21 2019-03-18 Methods for treating melanoma

Publications (4)

Publication Number Publication Date
JP2021518374A JP2021518374A (ja) 2021-08-02
JP2021518374A5 JP2021518374A5 (https=) 2022-03-15
JPWO2019182981A5 true JPWO2019182981A5 (https=) 2022-03-15
JP7229565B2 JP7229565B2 (ja) 2023-02-28

Family

ID=67987925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550082A Active JP7229565B2 (ja) 2018-03-21 2019-03-18 メラノーマを治療するための方法

Country Status (7)

Country Link
US (1) US11857529B2 (https=)
EP (1) EP3768384B1 (https=)
JP (1) JP7229565B2 (https=)
CN (1) CN111867678B (https=)
CA (1) CA3094307A1 (https=)
MX (1) MX2020009552A (https=)
WO (1) WO2019182981A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12121565B2 (en) * 2019-09-13 2024-10-22 Duke University Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies
WO2021076444A1 (en) 2019-10-14 2021-04-22 Olatec Therapeutics Llc Methods for treating breast cancer
JP2024534040A (ja) * 2021-08-19 2024-09-18 オラテック セラピューティクス， インコーポレイティド パーキンソン病の治療方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013006708A (es) * 2010-12-15 2013-09-13 Olatec Ind Llc Composicion de 3-metanosulfonilpropionitrilo para el tratamiento de la inflamacion y el dolor.
CA2875052C (en) * 2012-06-05 2020-07-14 Olatec Industries Llc Method for treating skin inflammatory diseases
CN104334165B (zh) * 2012-06-05 2017-09-05 欧拉泰克工业有限责任公司 用于治疗炎症和疼痛的药物组合物
SI3259253T1 (sl) * 2015-02-16 2020-07-31 The University Of Queensland Sulfonilsečnine in sorodne spojine ter njihova uporaba
US20160362489A1 (en) * 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
CA3021349A1 (en) * 2016-04-19 2017-10-26 Innate Tumor Immunity, Inc. Nlrp3 modulators
NL2017267B1 (en) * 2016-07-29 2018-02-01 Aduro Biotech Holdings Europe B V Anti-pd-1 antibodies
WO2018129231A1 (en) * 2017-01-06 2018-07-12 Olatec Therapeutics Llc Method for treating multiple sclerosis
EP3565540B1 (en) * 2017-01-06 2023-12-06 Olatec Therapeutics LLC A pharmaceutical composition for use in treating cardiovascular diseases
WO2018204764A1 (en) 2017-05-05 2018-11-08 Camp4 Therapeutics Corporation Identification and targeted modulation of gene signaling networks
WO2019152627A1 (en) * 2018-01-31 2019-08-08 Olatec Therapeutics Llc Method for preventing or treating alzheimer's disease

Similar Documents

Publication Publication Date Title
JP2021098728A5 (https=)
FI3849534T3 (fi) Yhdistelmähoidot
FI3788047T3 (fi) Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
CN114641293A (zh) 一种fgfr抑制剂的用途
JP2008505857A5 (https=)
JP2005503399A5 (https=)
CN109985237B (zh) 一种治疗结直肠癌的药物组合物及其应用
JP2021518374A5 (https=)
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
IL292265B2 (en) Methods for treating chronic lymphocytic leukemia using 2-(2,6-dioxopyridin-3-yl)-4-((2-fluoro-4((3-morpholinoazetidin-1-yl)methyl(benzyl(amino(amino(isoindoline-1. 3-dione)
CN101939001B (zh) 用于治疗卵巢癌的含有紫杉醇的组合
JP2021535175A5 (https=)
JP2024016209A5 (https=)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
RU2020115363A (ru) Каннабиноидная композиция и способ ее применения
JPWO2019182981A5 (https=)
CN115666576A (zh) 一种治疗和/或预防冠状病毒引发的疾病的化合物及其应用
FI3801515T3 (fi) 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa
RU2014125519A (ru) Ацил-гидразоновые и оксадиазоловые соединения, фармацевтические композиции, содержащие их, и их применение
RU2001129533A (ru) С 10 карбонат замещенные таксаны в качестве противоопухолевых агентов
JP2016196411A (ja) 腫瘍治療剤
JP2025060703A5 (https=)
JP2003055360A5 (https=)
AR130179A1 (es) Terapias combinadas para el tratamiento de la cirrosis con hipertensión portal
JP2006528190A5 (https=)